Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : announces FDA 510(k) submission for SleepCheckRx

10/10/2021 | 06:42pm EST

View printer-friendly version

  • ResApp has submitted a 510(k) premarket notification to the US FDA for SleepCheckRx
  • SleepCheckRx is a smartphone-only solution that uses clinically accurate algorithms to assess a patient's risk of obstructive sleep apnoea by analysing breathing and snoring sounds during sleep
  • 42 million American adults suffer from sleep disordered breathing, with 75% of cases undiagnosed

Brisbane, Australia, 11 October 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has submitted a 510(k) premarket notificationi to the US Food and Drug Administration (FDA) for SleepCheckRx, a prescription-only, software-as-a-medical-device (SaMD) smartphone application for at-home sleep apnoea screening. The targeted time period for review of a 510(k) application by the FDA is 90 days.

SleepCheckRx is ResApp's easy to use smartphone application that uses clinically accurate algorithms to assess a patient's risk of obstructive sleep apnoea (OSA) by analysing breathing and snoring sounds during sleep. It requires no accessories or hardware other than a smartphone to make an assessment.

In a 308 patient, prospective clinical study, the SleepCheckRx algorithms were tested against an American Academy of Sleep Medicine (AASM) Type II sleep study (full, but unattended polysomnography) performed simultaneously in the patient's home (ref ASX announcement 30 September 2019). In the study, the algorithms identified patients with mild (AHIii ≥ 5), moderate (AHI ≥ 15), and severe (AHI ≥ 30) OSA with a sensitivity of 85%, 83% and 83%, respectively. The algorithms had a specificity of 73%, 80% and 90%, respectively.

SleepCheckRx would be made available to patients via a prescription from their healthcare provider. Patients will be provided a specific code allowing them to download SleepCheckRx from the App Store, with their results uploaded to a healthcare provider portal.

FDA clearance would unlock a substantial market opportunity for ResApp. It is estimated that 42 million American adults suffer from sleep disordered breathing (SDB)iii and three in ten men and almost one in five women have sleep apnoeaiv. It is further estimated that 75% of SDB cases remain undiagnosedv.

CEO and Managing Director, Dr Tony Keating said: "This marks another important milestone for our sleep apnoea product line. Last year, we obtained TGA approval and CE Mark certification for our direct-to-consumer SleepCheck app which is now available in over 36 countries. This SleepCheckRx 510(k) submission is the first step in the review process with the FDA and we look forward to working with the FDA through the review to obtain clearance for SleepCheckRx.

Sleep apnoea is a serious sleep disorder and research tells us that most people in the US with sleep apnoea don't know they have it. With SleepCheckRx, physicians will have the opportunity to screen their patients conveniently and quickly for sleep apnoea, helping their patients take the first step in getting treatment."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

i https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k
ii Apnoea hypopnoea index (AHI) is the number of apnoeas or hypopnoeas per hour of sleep.
iii Young et al. New Engl J Med 1993
iv Peppard et al. Am J Epidemiol 2013
v Young et al. Sleep 2008

Disclaimer

ResApp Health Limited published this content on 11 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 October 2021 22:41:00 UTC.


ę Publicnow 2021
All news about RESAPP HEALTH LIMITED
11/29RESAPP HEALTH : receives world's first regulatory approvals for cough counter smartphone a..
PU
11/28ResApp Health Secures Australian, European Approvals for Cough Counter App; Shares Rise..
MT
11/28ResApp Receives Regulatory Approvals for Cough Counter
CI
11/23ResApp Health Completes Recruitment for COVID-19 Study in India
MT
11/22RESAPP HEALTH : completes COVID-19 study recruitment in India
PU
11/22ResApp Health Limited Completes COVID-19 Study Recruitment in India
CI
11/18RESAPP HEALTH : New publication highlights challenges of diagnosing acute respiratory dise..
PU
11/18Resapp Health Limited Announces Publication of Clinical Study Data Analysed from its Br..
CI
11/17Resapp Health Signs Deal with Johnson & Johnson Arm for Use of App in a Clinical Trial;..
MT
11/17RESAPP HEALTH : secures contract with global pharmaceutical company
PU
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,74 M -4,74 M
Net cash 2021 6,40 M 4,48 M 4,48 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 51,6 M 36,2 M 36,1 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 80,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-29.41%36
SNAP INC.-6.55%77 125
PERFECT WORLD CO., LTD.-34.81%5 821
KAKAO GAMES CORP.106.96%5 802
GRUBHUB INC.-19.36%5 591
ANGI INC.-30.28%4 622